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There is an urgent requirement for specific, sensitive and inexpensive dengue 
diagnostic tools that can be used for clinical management, surveillance and outbreak 
investigations   would permit early intervention to treat patients and prevent or control 
epidemics. Additionally, new techniques for the early detection of severe disease such as the 
use of biomarkers have the potential to decrease morbidity and mortality. Recent 
developments in rapid detection technologies offer the promise of improved diagnostics for 
case management and the early detection of dengue outbreaks.  This short review 
summarizes the various diagnostics tests currently pursued. 
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Dengue virus is currently one of the 
most important mosquito borne virus-
affecting people in more than 100 countries 
globally (WHO, 1997; Castleberry and 
Mahon,   2003). The disease is endemic 
mostly in tropical and sub-tropical areas and 
an evolving concern to other countries in 
Europe and USA (Rodriguez-Tan and Weir, 
1998; Malison and Waterman, 1983). Dengue 
fever is considered to be one of the significant 
emerging diseases in modern times with 
huge fatality both in terms of loss of life as 
well as economic impact particularly in 
developing countries. It is estimated that 
more than 3 billion people are at risk. 
Annually about 100 million cases of dengue 
fever and dengue hemorrhagic fever (DHF) 
are reported (Monath, 1994; Laue   et al. 1999; 
Guzman and Kouri, 1996). The potential 
threat of dengue disease increasing manifold 
stems from increased travel to and from 
endemic areas and new dengue virus strains 
being more and more exposed to susceptible 
populations particularly children. Due to the 
rapid spread of both virus and hosts, dengue 
has become an epidemic and an urgent 
public health concern, globally (Guzman and 
Kouri, 1996; Lupi and Tyring, 2003). Dengue 
viruses are single stranded RNA viruses that 
belong to the family Flaviviridae. There are 
four serotypes, i.e. DEN-1, DEN-2, DEN-3 
and DEN-4. Primarily the Aedes aegypti 
mosquitoes transmit these four serotypes to 
humans. Dengue virus is a positive-stranded 
encapsulated RNA virus wherein the 
genomic RNA is about 11 kb in size and 
comprises of three structural proteins 
(nucleocapsid protein (C), a membrane 
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associated protein (M), and envelope protein 
(E)), and seven nonstructural (NS) protein. 
Infection with any of the four serotypes 
induces a life-long protective immunity to 
that particular serotype but confers only 
partial immunity against later infections by 
the other three serotypes (Rice et al. 1985; 
Leyssen et al. 2000). Secondary infection with 
various dengue virus serotypes is a major 
risk factor for the more severe and often fatal 
DHF and the Dengue Shock Syndrome (DSS) 
due to the phenomenon of antibody-
dependent enhancement (ADE) (Halstead et 
al. 1973; Halstead, 1988).  
There is no available anti-dengue 
vaccine or therapy for the treatment of 
dengue infection infection (Sabchareon et al. 
2004). Development of a dengue vaccine is 
challenging primarily because it must be 
tetravalent so that it confers protection 
against all four serotypes and overcome 
ADE. Also there is no proper animal model 
for dengue vaccine trials. Some candidate 
vaccines are in various stages of clinical trials 
at the moment but an efficient, safe, low-cost 
vaccine is still some time away. Dengue 
infection can range has from asymptomatic 
infection to a more severe form of disease. 
There is also a possibility of additional 
complications in dengue cases such as 
hepatitis etc. (Mackenzie et al. 2004; Eltzov et 
al. 2010). The diagnostic tests must be able to 
address the infection at every level also 
differentiating between the serotypes 
simultaneously. Vector control efforts have 
also been extensively adopted in dengue 
endemic countries but results are far from 
satisfactory. There is an enormous potential 
and urgent requirement for rapid, 
inexpensive and sensitive diagnostic for 
detection of dengue so that timely palliative 
intervention can be pursued (Ananda Rao et 
al.  2005). There have been a variety of 
different diagnostic techniques currently 
being used. Some of the techniques 
commonly employed are virus isolation, 
Hemagglutination Inhibiton (HI), Plaque 
Reduction Neutralization Test (PRNT), 
polymerase Chain reaction (PCR) and 
Immunoassay for antibody detection 
(Vaughn et al. 1998, 1999; Palmer et al. 1999). 
Other novel technologies are aggressively 
pursued on the lines of better sensitivity, 
specificity, rapid and which would be cost 
effective. This mini commentary review 
existing and other diagnostic tools currently 
used for detection of dengue infection. 
 
Current diagnostics for dengue virus 
infection 
Simplified detection tests are very 
important for timely and accurate diagnosis 
of dengue for imparting proper care and 
treatment to the patients. As dengue is 
endemic in mostly developing countries 
which have to bear an enormous economic 
burden due to the disease, it is very 
important to develop a diagnostic test which 
would be low cost, sensitive, specific with 
least cross-reactivity, can be carried out with 
minimal training and above all the test must 
be rapid and can be performed at any setting 
(Blacksell, 2012). The most commonly used 
methods for detection of dengue virus 
infection are antibody detection assays, viral 
isolation and Polymerase Chain Reaction 
(PCR) based diagnostics.  Virus isolation has 
been so far considered as a standard protocol 
in identifying dengue infection. Virus 
isolation is carried out from clinical samples 
using mosquito cell lines such as AP-61, 
C6/36, etc (Guzman and Kouri, 1996; 
Kuberski and Rosen, 1977a). Associating 
immunofluorescence techniques with dengue 
specific monoclonal antibodies does the virus 
identification. Inoculating mosquitoes is one 
of the better methods for virus isolation 
inoculation owing to its higher sensitivity 
(Kuberski and Rosen, 1977a, 1977b).  Reports 
confirm that virus isolation from whole blood 
is more sensitive compared to serum.  But the 
necessity of proper infrastructure is a major 
deterrent for the routine use of this method. 
Another method of detection of dengue 
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infection is the detection of dengue viral 
antigens. ELISA based assays that detect the 
dengue non-structural protein 1 (NS1) are the 
most common methods employed as high 
concentrations of NS1 have been in reported 
in patients with primary as well as secondary 
dengue infections up to 10 days post disease 
onset (Das et al. 2009). NS1 localizes on the 
virus infected cells and subsequently secreted 
into the blood. An assay comprising of 
polyclonal and monoclonal antibodies as 
capture and detection antibodies along with 
purified NS1 from dengue infected cells as a 
standard was developed. Analysis of clinical 
samples with this assay signified the methods 
efficacy and more assays were developed 
having this basic principle many of which are 
being used commercially. Detecting viral 
antigens by indirect immunofluorescence 
assays have also been studied wherein 
monoclonal antibodies and fluorescein 
conjugated anti mouse or anti human 
antibodies are used. A visual end point 
constitutes a positive or a negative result. 
 Multiple methods have been pursued 
for the serological detection of dengue 
specific antibodies that include the HI test, 
PRNT, etc. The IgM /IgG ELISA, based on a 
sandwich format and the HI test are 
commonly used serological assays for 
diagnosis of dengue virus infections (Palmer 
et al. 1999). In the past, the HI test was used 
differentiate between primary and secondary 
dengue virus infections but lately antibody 
capture assays have been more popular 
(Palmer et al. 1999).  The HI test needs 
pretreatment to get rid of haemagglutination 
inhibitors and also the test is prone to 
flavivirus cross reactivity as well as serotype 
cross reactivity (Palmer et al. 1999).  Then 
there was the Complement fixation (CF) test 
which when compared to other tests has 
higher sensitivity in detecting primary 
dengue infections but the CF antibodies are 
found only after a week for a short period of 
time (WHO, 1999). Antibody detection 
ELISAs has become significant assays for the 
detection of dengue virus infection, the key 
advantages being its sensitivity and 
specificity. A number of kits are available in 
the market based on this principle (Innis et al. 
1989; Das et al. 2009; Bundo and Igarashi, 
1985). The Nucleic acid sequence based 
amplification or NASBA is an RNA 
amplification method based on chemi-
luminescence for detection of mRNA. This 
method has been successfully used to detect 
other pathogens such as malaria (Berndt et al. 
2000; Schoone  et al. 2000). This technology 
was then applied for the detection of dengue 
of all four serotypes and the results were 
comparable to a standard immune-
fluorescent-based virus isolation assay (Teles 
et al. 2005).  
 Dengue RNA can also be detected in 
clinical samples from humans or in 
mosquitoes by reverse-transcription– 
polymerase chain reaction (RT-PCR) 
amplification technique.   Dot blot 
immunoassay is yet another technique to 
diagnose dengue infection. The requirement 
for expensive infrastructure is a major 
drawback in the routine use of the 
methodology. Recombinant proteins domains 
of dengue virus serotypes were analyzed in 
strips to detect serotype specific antibodies in 
clinical samples and validated by PCR based 
diagnosis (Maniatis et al. 1982). Dengue virus 
antigens can also be visualized in samples 
with labeled monoclonal antibodies, end 
point visualization done with fluorescent 
dyes, enzymes, etc. Dengue Immunoglobulin 
G assays can be used for the diagnosis of 
earlier dengue infections as well as current 
infections if timely serum collection could be 
done. Assays are generally done using 
dilutions of each serum and used to 
determine a primary or a secondary infection. 
IgG based assays are very useful but it also 
has a major limitation that it is not serotype 
specific although the assay possess higher 
sensitivity than the HI assay. IgM based 
dengue diagnosis is also an useful tool 
commonly used in clinical settings. IgM 
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appears within 5 days of onset of illness and 
has both high specificity and sensitivity. The 
antigen purity is a major parameter in IgM 
based assays. There are a lot of commercial 
kits that use antigens from all the four 
serotypes in the assay thus determining any 
dengue infection and not being serotype 
specific. Since IgM circulates till about 3 
months post onset of illness, this assay is not 
a proper validation of a current infection. 
Nonetheless, rapid assays based on this 
principle have been developed for point of 
care applications.   
 The continued and concerted effort in 
developing low cost and sensitive diagnostic 
applications for dengue is praiseworthy but 
more research is needed to overcome the 
many limitations of the existing technologies. 
Virus isolation is a time intensive process, 
requires skilled personnel and expensive 
infrastructure and cannot distinguish 
between a primary and secondary dengue 
virus infection. RNA amplification also 
requires expensive set up and technically 
trained personnel. The dengue antigen 
detection assays are simple, rapid and 
inexpensive but lacks the sensitivity of a viral 
isolation or nucleic acid amplification 
technique. Another important parameter is 
the proper validation and effectiveness of the 
various commercial assays particularly in the 
developing countries (Peeling et al. 2010). The 
need of the hour is to improve upon the 
existing technologies by minimizing the 
drawbacks and the simultaneous persuasion 
of new technologies such as the use of 
biosensors. A biosensor based on liposomal 
amplification was developed to diagnose 
serotype specific synthetic dengue sequence.   
Promising outcomes have been reported but 
a lot of research has to be done to take the 
technology to the next level. Biosensor based 
detection has the potential to be more 
sensitive than conventional assays but the 
technology needs to overcome constraints 
such as interference issues between 
electrochemical substances and the 
unpredictability of the biomolecule 
immobilization on the sensor surface which 
may impact both sensitivity and specificity.   
 
Future direction and conclusion 
Dengue diagnostics has made 
considerable progress with novel 
technologies being evolved and significant 
improvements made on the existing methods 
but there is still an enormous potential 
towards an ideal detection system that would 
be simple, inexpensive, rapid, sensitive and 
specific. The development of immunoassays 
based on NS1 antigen has been very 
significant and this has led to a number of 
commercial kits that are largely used around 
the world. The use of bi-specific antibodies in 
NS1 based immunoassays can significantly 
enhance the sensitivity of the existing assay 
due to their monovalency for an antigen as 
well as simultaneous binding to an enzyme. 
Bi-specific antibodies are engineered bi-
functional molecules having dual binding 
specificities in a single entity. Bi-specific 
antibodies have been successfully exploited 
in the development of immunodiagnostic 
assays (Kreutz and Suresh, 1997; Kammila et 
al. 2008; Sarkar et al. 2012; Malabadi et al. 
2012;  Khan et al. 2011, 2012). Our laboratory 
has developed a sensitive low cost 
immunoassay employing bi-specific 
antibodies for the diagnosis of dengue. The 
assay has many positives such as specificity, 
inexpensive, rapid and can be performed in 
any point of care setting by personnel with 
minimal technical expertise without the use 
of complex instruments (Malabadi, 2008; 
Malabadi et al. 2010, 2011, 2012).  Such novel 
diagnostic in combination with other existing 
technologies needs to be evolved to provide 
timely therapeutic intervention to tackle the 
fatal disease.  
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